EA9161
|
Alliance
|
A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA9171
|
Alliance
|
BLAST MRD CML 1 Trial: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML and Persistently Detectable MRD
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA9181
|
ECOG-ACRIN
|
A Phase III Randomized Trial of Steroids +Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia in Adults
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA9213
|
ECOG-ACRIN
|
A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EAA171
|
ECOG-ACRIN
|
Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EAA172
|
ECOG-ACRIN
|
Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone with or without Venetoclax in Relapsed/Refractory Multiple Myeloma with Assessment for t(11;14) Status
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
EAA173
|
ECOG-ACRIN
|
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EAA181
|
ECOG-ACRIN
|
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended For Early Autologous Transplantation
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EAE161
|
ECOG-ACRIN
|
Perfusion CT to Predict Progression-free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
EAF151
|
ECOG-ACRIN
|
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|